Chinese General Practice ›› 2023, Vol. 26 ›› Issue (32): 3975-3994.DOI: 10.12114/j.issn.1007-9572.2023.0408

Special Issue: 心血管最新文章合集

• Cardiovascular Research Development Report •     Next Articles

Interpretation of Report on Cardiovascular Health and Diseases in China 2022

  

  1. National Center for Cardiovascular Diseases/Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing 100037, China
  • Received:2023-06-30 Revised:2023-07-15 Published:2023-11-15 Online:2023-07-18
  • Contact: HU Shengshou

《中国心血管健康与疾病报告2022》要点解读

  

  1. 100037 北京市,国家心血管病中心 中国医学科学院阜外医院
  • 通讯作者: 胡盛寿

Abstract:

Due to the acceleration of population aging and the prevalence of unhealthy lifestyles, the huge population with cardiovascular disease (CVD) risk factors, the burden of CVD continues to increase in China. CVD is still the leading cause of death among urban and rural residents in China. In 2020, CVD accounted for 48.00% and 45.86% of the causes of death in rural and urban areas, respectively, and two out of every five deaths were due to CVD. It is estimated that the number of current CVD patients in China is 330 million, including 13 million cases of stroke, 11.39 million cases of coronary heart disease, 8.9 million cases of heart failure, 5 million cases of pulmonary heart disease, 4.87 million cases of atrial fibrillation, 2.5 million cases of rheumatic heart disease, 2 million cases of congenital heart disease, 45.3 million cases of peripheral artery disease, and 245 million cases of hypertension. The total hospitalization costs were 270.901 billion yuan for CVD in China in 2020. The prevention and treatment of CVD in China still has a long way to go. In general, we should not only do a good job in secondary prevention and treatment of CVD, but also further strengthen the upstream treatment of modifiable risk factors such as hypertension, hyperglycemia and hyperlipidemia starting with both preventive treatment and treatment diseases. In addition, attention should be paid to the allocation and prioritization of health care and public health resources, so as to reach the inflection point of CVD prevention and treatment as early as possible.

Key words: Cardiovascular disease, Epidemiology, Health influencing factors, Risk factors, Prevalence, Mortality, Community-based prevention and control, Rehabilitation, Basic research, Medical device development, Fees, medical

摘要:

由于中国人口老龄化进程的加速以及不健康生活方式的流行,存在心血管病(CVD)危险因素的人群巨大,中国CVD负担持续加重。在我国城乡居民疾病死亡构成比中,CVD仍居首位。2020年,农村、城市CVD分别占死因的48.00%和45.86%,每5例死亡中就有2例死于CVD。推算我国CVD现患人数3.3亿,其中脑卒中1 300万,冠心病1 139万,心力衰竭890万,肺源性心脏病500万,心房颤动487万,风湿性心脏病250万,先天性心脏病200万,外周动脉疾病4 530万,高血压2.45亿。2020年中国心脑血管疾病的住院总费用合计为2 709.01亿元。CVD防治工作仍然任重道远。总的来说,我国应从"已病"和"未病"双重着手,既要做好CVD的二级预防治疗,还应进一步强化高血压、高血糖、高血脂等可调节危险因素的上游治疗,并注重卫生保健和公共卫生资源的分配和优先次序,以期更早地迎来CVD防治拐点。

关键词: 心血管疾病, 流行病学, 健康影响因素, 危险因素, 患病率, 死亡率, 社区防治, 康复, 基础研究, 器械研发, 费用,医疗